Silicon Valley software company DigiSight Technologies Inc has received $7.8 million in Series B funding. The backers included Biosys Capital, Waycross Ventures, GE Ventures and Lagunita LLC.
PORTOLA VALLEY, Calif.–(BUSINESS WIRE)–DigiSight Technologies, Inc. (DigiSight), a software company that integrates data from mobile tests into clinical settings, today announced it raised $7.8 million in a Series B financing. New investors Biosys Capital, Waycross Ventures, GE Ventures, and Lagunita LLC joined existing investors in the financing.
DigiSight’s core technology, called the DigiSight Network™, creates a secure connection for data from mobile devices to move seamlessly into clinical settings. The first specialty in the company’s commercialization strategy is ophthalmology. Patients generate ophthalmic data using mobile devices and share that data with permissioned care providers in real-time. These tests provide physicians insight into patient performance between regular office examinations, unlocking the true potential of remote patient monitoring and data analytics. The company will use the proceeds from the financing to continue developing the DigiSight Network™ and other specialized remote monitoring technologies with an expanded team.
Drs. Mark Blumenkranz and Daniel Palanker of Stanford University founded the company with the belief that mobile technologies can help deliver care more efficiently. Dr. Blumenkranz is the H.J. Smead Professor and Chairman of the Department of Ophthalmology at Stanford University. He is also a serial entrepreneur and has founded and been a board member of a number of successful companies including Avalanche Biotechnologies (Nasdaq:AAVL), Optimedica Corporation and PEAK Surgical. Dr. Palanker is a Professor of Ophthalmology at the Hansen Experimental Physics Laboratory at Stanford University. He was a co-founder of PEAK Surgical and developed foundational technologies for Optimedica Corporation. He is an expert in light and laser-based systems in ophthalmology.
Boris Nikolic of Biosys Capital stated, “DigiSight is the leading mobile healthcare company in ophthalmology. Its vision to integrate mobile diagnostics into clinical care will be a keystone to streamlining the delivery of care to patients that need it most. As an investor and user of DigiSight’s products, I could not be more excited to participate in this financing that will enable the company to execute its plan, build the team and bring new products to the market.”
DigiSight Technologies CEO, Doug Foster, said, “Ophthalmology is a specialty well-suited to using mobile tests and diagnostics. Blindness is a debilitating condition that is expensive for the healthcare system, and patients with acute conditions are highly motivated to be engaged with their care plans. Generating more patient data can profoundly impact the ability to deliver high quality, cost-efficient care for these patients.
DigiSight is leading the movement to realize this vision for healthcare through mobile technology. This financing enables us to move aggressively on our plan and we are excited to partner with our new investors.”
About DigiSight Technologies, Inc.:
DigiSight Technologies, Inc., is a privately held Silicon Valley software company focused on bridging the gap between healthcare providers and patients with mobile tests. DigiSight links patient and doctor by offering a single, secure portal for providers to access diagnostic data in real time. This portal unites information across various data creation devices into a single database, enabling providers to realize the full potential of remote patient monitoring and data analytics. For more information, please visit www.digisight.net.